Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine for Late-Life Treatment Resistant Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 50 years~* Major depressive disorder~* Non-responder to at least 2 FDA-approved antidepressants prescribed at a therapeutic dose, each for at least 6 weeks, or is a depression non-responder from an ongoing study of late-life depression at our research clinic.~Exclusion Criteria:~* Concomitant use of strong or moderate CYP3A4 inhibitor.~* Refusal to stop all opioids.~* Refusal to discontinue all alcohol.~* Refusal to discontinue benzodiazepines other than the equivalent of lorazepam 2 mg/day prescribed at a stable dose for at least the past 2 weeks.~* Hepatic impairment (AST/ALT \> 1.5 times upper normal.~* Lung disease requiring supplemental oxygen.~* Estimated creatinine clearance \<30 mL/min.~* Inability to provide informed consent.~* Depressive symptoms not severe enough (i.e., MADRS \< 10) at the baseline assessment.~* Dementia.~* Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms.~* Abuse of or dependence on alcohol or other substances within the past 3 months.~* Meets criteria for history of abuse or dependence upon opioids.~* High risk for suicide.~* Contraindication to buprenorphine.~* Inability to communicate in English.~* Non-correctable clinically significant sensory impairment.~* Unstable medical illness.~* Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Buprenorphine (Type: EXPERIMENTAL): Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).